Hikma to divest rights to five drugs in exchange for acquiring new drugs
Hikma Pharmaceuticals must sell the rights to five generic injectable drugs to Amphastar Pharmaceuticals in order to acquire drug rights from Ben Venue Laboratories....To view the full article, register now.
Already a subscriber? Click here to view full article